BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18358555)

  • 1. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.
    Ersoy C; Kiyici S; Budak F; Oral B; Guclu M; Duran C; Selimoglu H; Erturk E; Tuncel E; Imamoglu S
    Diabetes Res Clin Pract; 2008 Jul; 81(1):56-60. PubMed ID: 18358555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of metformin and diet on plasma testosterone and leptin levels in obese men.
    Ozata M; Oktenli C; Bingol N; Ozdemir IC
    Obes Res; 2001 Nov; 9(11):662-7. PubMed ID: 11707532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
    Glueck CJ; Fontaine RN; Wang P; Subbiah MT; Weber K; Illig E; Streicher P; Sieve-Smith L; Tracy TM; Lang JE; McCullough P
    Metabolism; 2001 Jul; 50(7):856-61. PubMed ID: 11436194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.
    Kiyici S; Ersoy C; Kaderli A; Fazlioglu M; Budak F; Duran C; Gul OO; Sigirli D; Baran I; Tuncel E; Erturk E; Imamoglu S
    Diabetes Res Clin Pract; 2009 Oct; 86(1):44-50. PubMed ID: 19674806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance.
    de Aguiar LG; Bahia LR; Villela N; Laflor C; Sicuro F; Wiernsperger N; Bottino D; Bouskela E
    Diabetes Care; 2006 May; 29(5):1083-9. PubMed ID: 16644641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes.
    Fanghänel G; Silva U; Sanchez-Reyes L; Sisson D; Sotres D; Torres EM
    Rev Invest Clin; 1998; 50(5):389-94. PubMed ID: 9949668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study.
    Gao H; Xiao W; Wang C; Zhang J; Yang Y; Yang J; Yang W; Hong T
    Int J Clin Pract; 2008 May; 62(5):695-700. PubMed ID: 18412932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of metformin in type 2 diabetes.
    Eriksson A; Attvall S; Bonnier M; Eriksson JW; Rosander B; Karlsson FA
    Diabetes Obes Metab; 2007 Jul; 9(4):483-9. PubMed ID: 17587390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
    Andreadis EA; Katsanou PM; Georgiopoulos DX; Tsourous GI; Yfanti GK; Gouveri ET; Diamantopoulos EJ
    Exp Clin Endocrinol Diabetes; 2009 Apr; 117(4):175-80. PubMed ID: 19053032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of short-term glycemic regulation with gliclazide and metformin on postprandial lipemia.
    Emral R; Köseoğlulari O; Tonyukuk V; Uysal AR; Kamel N; Corapçioğlu D
    Exp Clin Endocrinol Diabetes; 2005 Feb; 113(2):80-4. PubMed ID: 15772898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients.
    Lucotti P; Setola E; Monti LD; Galluccio E; Costa S; Sandoli EP; Fermo I; Rabaiotti G; Gatti R; Piatti P
    Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E906-12. PubMed ID: 16772327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
    Rigla M; Wägner AM; Borrell M; Mateo J; Foncuberta J; de Leiva A; Ordóñez-Llanos J; Pérez A
    Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total and acylated ghrelin levels in type 2 diabetic patients: similar levels observed after treatment with metformin, pioglitazone or diet therapy.
    Kiyici S; Ersoy C; Oz Gul O; Sarandol E; Demirci M; Tuncel E; Sigirli D; Erturk E; Imamoglu S
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):386-90. PubMed ID: 19629933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin in the treatment of obesity in subjects with normal glucose tolerance.
    Tankova T; Dakovska L; Kirilov G; Koev D
    Rom J Intern Med; 2003; 41(3):269-75. PubMed ID: 15526510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes.
    Wagner H; Degerblad M; Thorell A; Nygren J; Ståhle A; Kuhl J; Brismar TB; Ohrvik J; Efendic S; Båvenholm PN
    Diabetes Care; 2006 Jul; 29(7):1471-7. PubMed ID: 16801564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An exercise intervention without weight loss decreases circulating interleukin-6 in lean and obese men with and without type 2 diabetes mellitus.
    Dekker MJ; Lee S; Hudson R; Kilpatrick K; Graham TE; Ross R; Robinson LE
    Metabolism; 2007 Mar; 56(3):332-8. PubMed ID: 17292721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.